We have read the article by Zivlas and colleagues in which the authors suggest a putative pathogenic role for cystatin C (Cys-C) and galectin-3 (Gal-3) in heart failure (HF) progression and cardiorenal syndrome. They even speculate on the possibility of targeting both molecules as a new therapeutic approach to address both processes. 1 We strongly disagree with this point of view. The authors seem to have missed important information concerning the pathophysiological role of these biomarkers in cardiovascular diseases.
Cys-C has been extensively studied in the context of HF. It is largely accepted nowadays that Cys-C is a fine surrogate marker of glomerular filtration rate (GFR), 2 and not involved in heart remodelling 3 nor in the pathogenesis of cardiovascular diseases. 4 Similarly, the initial hope with Gal-3, has been dismantled by studies showing that it is, again, merely a marker of GFR that does not add prognostic information after correcting for renal function, 5 nor is it involved in the pathogenesis of fibrotic changes at a myocardial level in HF from hypertensive origin. 6 Risk stratification remains a key point in HF, 7 and for that purpose, Cys-C is an excellent option, especially for patients with a mild impairment in GFR, where it has been shown to reclassify up to 20% of patients. 8 Further applications of both biomarkers, especially in the field of therapeutics remain largely speculative with little likelihood of reaching practical goals.
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